Teva Pharmaceutical Industries, the world’s leading manufacturer of generic drugs, is expected to face a significant antitrust fine from the EU in the coming weeks.
The fine stems from allegations that the Israeli pharmaceutical giant engaged in anti-competitive behavior related to its popular multiple sclerosis medication, Copaxone. Sources with direct knowledge of the situation revealed that Teva is accused of disparaging rival products to maintain Copaxone’s market dominance.
The European Commission’s investigation, which began with dawn raids in 2019 and led to formal proceedings in 2021, centers on claims that Teva misused the patent system. The Commission contends that Teva’s actions were designed to artificially prolong Copaxone’s patent protection and prevent competition. This enforcement action reflects the EU’s broader concerns about practices that might hinder innovation in the pharmaceutical sector, especially in a landscape constrained by tight healthcare budgets.
Related: FTC Intervenes in Teva’s Inhaler Litigation Against Amneal Amid Patent Crackdown
Bloomberg reports that the European Commission has not commented on the impending fine, and Teva has not yet responded to requests for a statement. The Commission’s rigorous stance underscores the EU’s commitment to addressing anti-competitive practices that could impact market dynamics and drug affordability.
In a related development, Teva and its subsidiary Cephalon faced a fine of 60.5 million euros ($66.7 million) in 2020 for engaging in pay-for-delay schemes, where they agreed to delay the release of a cheaper generic version of Cephalon’s sleep disorder medication. This fine was part of a broader EU crackdown on such practices between brand-name drugmakers and their generic counterparts.
Source: Bloomberg
Featured News
US Judge OKs $110 Million Settlements in Antitrust Case Against Major Real Estate Brokerages
Oct 31, 2024 by
CPI
50 States and Territories Reach $49.1 Million Settlement in Generic Drug Price-Fixing Case
Oct 31, 2024 by
CPI
OpenAI Enhances ChatGPT with New Search Feature, Challenging Google’s Dominance
Oct 31, 2024 by
CPI
First Circuit Hears Arguments on Whether Federal Baseball Antitrust Exemption Shields Puerto Rican League from Legal Claims
Oct 31, 2024 by
CPI
Federal Appeals Court Expresses Doubts Over FCC’s Authority in Net Neutrality Revival
Oct 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI